Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
News
Adding elraglusib, a small molecule being developed by Actuate Therapeutics, to standard chemotherapy with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for metastatic…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
Treatment with Zynlonta (loncastuximab tesirine) is helping to push high-risk follicular lymphoma and marginal zone lymphoma into complete remission for a majority of the…
Bizengri (zenocutuzumab-zbco) is now approved in the U.S. as the first treatment for advanced pancreatic cancer and non-small cell lung cancer (NSCLC) harboring an…
Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based therapy, for pediatric recurrent high-grade…
Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than chemotherapy alone in women with…
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
